Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

This article was originally published in PharmAsia News

Executive Summary

The Novartis Institute For Tropical Diseases is developing new drugs for tuberculosis, dengue fever and malaria with the goal of moving a candidate into the clinic for TB as soon as year-end, Novartis' Head of Corporate Research Paul Herrling told "The Pink Sheet" DAILY in a recent interview

You may also be interested in...



Sanofi Pasteur To Launch Pediatric Dengue Fever Vaccine Trial In Thailand

HONG KONG - Pediatric clinical trials on the first vaccine for dengue fever are set to start in a province in Thailand

Sanofi Pasteur To Launch Pediatric Dengue Fever Vaccine Trial In Thailand

HONG KONG - Pediatric clinical trials on the first vaccine for dengue fever are set to start in a province in Thailand

Novartis Coartem Malaria NDA May Be First For Priority Review Voucher

Novartis' pending application for approval of the malaria treatment Coartem (artemether/lumefantrine) puts the company in line to be among the first to obtain a priority review voucher from FDA

Related Content

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel